MDLZ
Mondelez International, Inc.
MDLZ's fundamentals are strong: free cash flow grew 60% and its operating margin rose 3 points to 14%. At 21x earnings, it's trading in line with its usual 22x. Analysts expect that strong growth to continue.
MDLZ Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Stable |
MDLZ's profitability and cash flow are currently healthy, and its revenue and balance sheet are stable.
MDLZ PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 20x | $64.07 | -3.7% |
| Forward | 20x | $66.56 | — |
| Current | 21x | $66.56 | — |
| Fair | 22x | $71.08 | +6.8% |
| Expensive | 26x | $83.55 | +26% |
Historical ranges are pointers, not guarantees.
MDLZ's PE is in its cheap range at 21x. If earnings grow as analysts expect, today's price would be 20x next year's earnings.
MDLZ Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Strong growth | |
| Stable | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect MDLZ's earnings to grow and its profitability to improve, with its revenue holding steady.
MDLZ Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.31 | +4.1% |
| Q3 2026 | $3.18 | +19% |
| Q2 2026 | $2.73 | 0% |
| Q1 2026 | $2.02 | -25% |
| Q4 2025 | $1.89 | -45% |
| Q3 2025 | $2.67 | -5% |
| Q2 2025 | $2.73 | -5.9% |
| Q1 2025 | $2.69 | -14% |
| Q4 2024 | $3.42 | -5.5% |
MDLZ earned $3.18 per share over the past year, up 19% from the year before.
MDLZ Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $10B | +2.3% |
| Q2 2026 | $9.4B | +4.1% |
| Q1 2026 | $10.1B | +8.2% |
| Q4 2025 | $10.5B | +9.3% |
| Q3 2025 | $9.7B | +5.9% |
| Q2 2025 | $9B | +7.7% |
| Q1 2025 | $9.3B | +0.2% |
| Q4 2024 | $9.6B | +3.1% |
MDLZ's revenue has grown year over year for nine quarters in a row: $10B last quarter, up 2.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 18% | +10 points |
| Q2 2026 | 21% | +7.8 points |
| Q1 2026 | 8% | +0.7 points |
| Q4 2025 | 9.1% | -7.7 points |
| Q3 2025 | 7.6% | -4.9 points |
| Q2 2025 | 13% | +2.8 points |
| Q1 2025 | 7.3% | -22 points |
| Q4 2024 | 17% | +4 points |
MDLZ's operating margin was 18% last quarter, up 10 points from the same quarter a year ago.
MDLZ Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $991M | +137% |
| Q2 2026 | $513M | +17000% |
| Q1 2026 | $155M | -81% |
| Q4 2025 | $2B | +90% |
| Q3 2025 | $418M | -58% |
| Q2 2025 | $3M | -99% |
| Q1 2025 | $815M | -20% |
| Q4 2024 | $1.1B | -14% |
MDLZ's free cash flow has been positive every quarter for seven years: $3.7B over the past year, up 60% from the year before.
MDLZ Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.5% | -7M shares |
| 1 year | -1.2% | -16M shares |
| 3 years | -6.6% | -90M shares |
| 5 years | -9.1% | -128M shares |
| Available history | -12% | -173M shares |
MDLZ has 1.3B diluted shares, down 1.2% from a year ago, with $1.3B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $633M |
| Q2 2026 | $212M |
| Q1 2026 | — |
| Q4 2025 | $492M |
| Q3 2025 | $240M |
| Q2 2025 | $131M |
| Q1 2025 | $1.5B |
| Q4 2024 | $1.1B |
MDLZ spent $1.3B buying back its own shares over the past year, down 56% from the year before.
MDLZ Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.9x | Moderate |
| Q2 2026 | 3.4x | Elevated |
| Q1 2026 | 3.8x | Elevated |
| Q4 2025 | 3.9x | Elevated |
| Q3 2025 | 3.6x | Elevated |
| Q2 2025 | 3.3x | Elevated |
| Q1 2025 | 3.2x | Elevated |
| Q4 2024 | 2.1x | Moderate |
MDLZ's net debt is about 2.9 years of its operating earnings (EBITDA), down from 3.6 years a year ago.
MDLZ Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 62.7 | Neutral |
| Stochastic | 79.5 | Neutral |
MDLZ's weekly RSI is 63 (neutral) and its Stochastic is 80 (neutral).
MDLZ PE vs Consumer Defensive Sector
| Metric | MDLZ | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 19x | 7.4% above |
| PE % | 28 | 18 | 10 pts above |
MDLZ is trading at 21x earnings, in line with the Consumer Defensive sector's median of 19x.
MDLZ Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $63.0 | 5.6% above |
| 20 week MA | $62.3 | 6.9% above |
| 50 week MA | $60.0 | 11% above |
| 100 week MA | $61.6 | 8% above |
| 200 week MA | $65.9 | 1.1% above |
MDLZ has climbed back above all five of its weekly moving averages, and it's now 1.1% above its 200-week average.
MDLZ Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $55.3 | $57.9 | +4.6% |
| 2021 | $57.9 | $64.9 | +12% |
| 2022 | $64.9 | $67.1 | +3.3% |
| 2023 | $67.1 | $72.4 | +7.9% |
| 2024 | $72.4 | $60.2 | -17% |
| 2025 | $60.2 | $54.6 | -9.3% |
| 2026 YTD | $54.6 | $66.6 | +22% |
MDLZ has finished higher in four of the last six years. It's up 22% so far in 2026.